Department of Nephrology, Bengbu Hospital of Shanghai General Hospital, The Second Affiliated Hospital of Bengbu Medical University, No. 633, Longhua Road, Huaishang District, Bengbu, 233040, China.
Department of Pediatrics, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233040, China.
Sci Rep. 2024 Oct 14;14(1):24017. doi: 10.1038/s41598-024-73154-9.
This study explores the feasibility, safety, and efficacy of percutaneous transluminal angioplasty (PTA) for reinserting tunneled cuffed catheters (TCC) with a Dacron sheath in the right internal jugular vein (RIJV) in hemodialysis patients with a history of prior RIJV catheterization and subsequent stenosis or occlusion of the RIJV, right innominate vein, and superior vena cava. Clinical data from 21 hemodialysis patients with dysfunctional vascular access who underwent PTA for reinsertion of TCC in the RIJVs from July 2020 to June 2023 at the First and Second Affiliated Hospitals of Bengbu Medical College were retrospectively analyzed. Clinical efficacy during hospitalization, postoperative TCC blood flow, and related complications during follow-up were observed. The procedure was successful in all 21 patients, with postoperative TCC blood flow meeting daily hemodialysis requirements. Only one case experienced acute bleeding with contrast agent extravasation at the intersection of the left and right innominate veins during sharp recanalization. No severe complications, such as arrhythmias, vascular rupture, pneumothorax, mediastinal hematoma, or pericardial tamponade, occurred during the procedures. Upon discharge, all patients exhibited satisfactory TCC blood flow (247.14 ± 11.46 ml/min). Postoperatively, TCC blood flow ranged between 200 and 260 ml/min, meeting the demands of regular hemodialysis. For patients with a history of repeated TCC or non-tunneled catheter (NTC) placement in the RIJV, reinserting TCC in the RIJVs through PTA is a safe and reliable technique. It effectively utilizes vascular resources and prevents vascular resource depletion associated with changing the venous catheter placement location.
本研究探讨了经皮腔内血管成形术(PTA)用于重新插入带涤纶套隧道导管(TCC)在右颈内静脉(RIJV)的可行性、安全性和疗效,这些患者既往有 RIJV 导管置入史,随后出现 RIJV、右无名静脉和上腔静脉狭窄或闭塞,且为血液透析患者。回顾性分析 2020 年 7 月至 2023 年 6 月蚌埠医学院第一附属医院和第二附属医院 21 例因血管通路功能障碍行 PTA 治疗以重新插入 RIJV 内 TCC 的血液透析患者的临床资料。观察患者住院期间的临床疗效、术后 TCC 血流情况及随访期间相关并发症。21 例患者均手术成功,术后 TCC 血流满足每日血液透析需求。仅 1 例在锐性再通时出现左、右无名静脉交界处对比剂外渗急性出血。在手术过程中,无严重并发症,如心律失常、血管破裂、气胸、纵隔血肿或心包填塞。出院时,所有患者的 TCC 血流均满意(247.14 ± 11.46 ml/min)。术后 TCC 血流在 200-260ml/min 之间,满足常规血液透析的要求。对于有重复 TCC 或非隧道导管(NTC)置入 RIJV 病史的患者,通过 PTA 重新插入 RIJV 内 TCC 是一种安全可靠的技术。它有效地利用了血管资源,防止了因改变静脉导管放置位置而导致的血管资源枯竭。